<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159563">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01655394</url>
  </required_header>
  <id_info>
    <org_study_id>01607831337</org_study_id>
    <nct_id>NCT01655394</nct_id>
  </id_info>
  <brief_title>Change of Nerve Conduction Properties in IVIg Dependent Neuropathies</brief_title>
  <official_title>Change of Nerve Conduction Properties in IVIg Dependent Neuropathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <authority>Germany: University of Cologne</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IVIg exert a variety of different immunomodulatory effects and several mechanism of action
      have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction
      in patients with immune-mediated neuropathies will be explored.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Guillain-Barre Syndrome</condition>
  <condition>CIDP</condition>
  <condition>Multifocal Motor Neuropathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with immune neuropathies
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  immune neuropathy

          -  age above 18 y

          -  IVIg treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helmar C. Lehmann, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helmar C. Lehmann, PD Dr. med.</last_name>
    <email>helmar.lehmann@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmar Lehmann, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Helmar Lehmann</investigator_full_name>
    <investigator_title>PD Dr. med. H. Lehmann</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Guillain-Barre Syndrome</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
